Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free fluoroquinolone antibiotic cases. Here at Leading Justice, we can custom-tailor your firm’s Levaquin, Avelox and Cipro advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of fluoroquinolone antibiotic advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to see if it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Levaquin, Cipro and Avelox, and side effects like aortic aneurysm, aortic dissection and peripheral neuropathy, Leading Justice will increase your firm’s fluoroquinolone antibiotic case load. If you are interested in helping victims of alleged Levaquin, Cipro or Avelox side effects, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence to allocate your full budget, knowing that your money is being spent in the best way possible.
Each law firm we work with plays an integral role in how we classify claims as qualified or not. Our years of experience working with plaintiff law firms helps us recognize a great case when we see one, but we will also customize our Levaquin, Cipro and Avelox case intake specifications to the exact criteria you are seeking. If your firm has specific fluoroquinolone antibiotic qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Levaquin, Avelox and Cipro data with zero chance of fraud.
Levaquin, Cipro, Avelox and Aortic Aneurysm Litigation
Levaquin, Cipro and Avelox belong to class of antibiotic drugs called fluoroquinolones, which are commonly prescribed to patients suffering from bacterial infections and other conditions. Over the past 20 years, millions of Americans have been prescribed fluoroquinolone antibiotic drugs like Levaquin, Cipro and Avelox, which is alarming, considering the fact that these medications have been linked to a significantly increased risk of nerve damage and aortic aneurysm or dissection, damage to the main artery that supplies blood to the rest of the body, which can cause the aorta to rupture or leak. This damage to the aorta may lead to potentially life-threatening complications like internal bleeding, heart attack, stroke, blood clots and death.
In late 2015, two studies were published in the British Medical Journal and JAMA Internal Medicine highlighting the potential for fluoroquinolone antibiotics like Levaquin, Avelox and Cipro to cause aortic aneurysm and dissection side effects in users. In the BMJ study, researchers found a nearly three-fold higher risk of aortic aneurysm in patients taking fluoroquinolones, and in the JAMA study, they found a two-fold higher risk of aortic aneurysm and aortic dissection occurring within 60 days of beginning fluoroquinolone treatment. As more information comes to light about the risk of aortic aneurysm from fluoroquinolone drugs, attorneys across the country are investigating injury claims filed on behalf of patients who believe they have been adversely affected by side effects of Levaquin, Cipro or Avelox.
